Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database.

The incidence of PTLD per 1000 patient-years at risk was higher at each yearly post-transplant time point for patients in the belatacept versus CNI treatment group, but the differences did not reach statistical significance in that the 95% CIs overlapped ( Table 5 ).

also in 111,027 other papers